Description

Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.

Primary FDA-studied route with extensive clinical data. Maximum immune modulation through systemic circulation. Established dosing protocols from 35+ countries of clinical use.

Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function through systemic circulation.

Immunity:

Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence in clinical trials.

Vaccine Response Enhancement
Enhances immunogenicity in elderly and hemodialysis patients with improved antibody responses to H1N1 and COVID-19 vaccines.

HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections in HIV patients with sustained immunological improvement.

Inflammation:

Cytokine Storm Mitigation
Reduces pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 by 40-60% while maintaining balanced immune responses in COVID-19 and sepsis.

Chronic Inflammatory Conditions
Modulates inflammatory responses in hepatitis B/C, pancreatitis, and autoimmune conditions through TLR pathway regulation.

Recovery:

Post-Surgical Immune Recovery
Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration and thymic function support.

Exercise-Induced Immunosuppression
Counters stress-induced immune suppression in athletes and high-stress situations through cortisol pathway modulation.

Anti Aging:

Thymic Regeneration
Supports age-related thymic decline through hormone replacement therapy and enhanced T-cell production in elderly populations.

Immune Senescence Prevention
Delays age-related immune system deterioration with improved vaccine responses and reduced infection susceptibility.

Celluar:

Antioxidant Enzyme Enhancement
Increases SOD and glutathose peroxidase activity providing cellular protection against oxidative damage.

Mitochondrial Function Support
Supports cellular energy metabolism and protects against age-related mitochondrial decline.